Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trading Halts

Neurocrine Bio. (NBIX) PT Lowered to $102 at H.C. WainwrightDecember 13, 2018 11:09 AM Neurocrine Bio. (NBIX) PT Lowered to $105 at OppenheimerDecember 13, 2018 9:30 AM Neurocrine Bio. (NBIX) PT Lowered to $96 at Baird, Removed from 'Fresh Pick' ListDecember 12, 2018 12:16 PM Neurocrine Bio. (NBIX) PT Lowered to $104 at Needham & CompanyDecember 12, 2018 10:48 AM Neurocrine Biosciences (NBIX) to Resume Trading at 8 am ETDecember 12, 2018 7:34 AM Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette SyndromeDecember 12, 2018 7:30 AM